FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results
Related Articles
Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Mobi Health News: Anumana, a joint venture between EHR data company nference and the Mayo Clinic, entered into a multiyear partnership with Pfizer to develop an AI-based tool for the…{post_date: F d, Y}
The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption
Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those that are poised for adoption. Across healthcare, AI-enabled diagnostic solutions…{post_date: F d, Y}
Mayo Clinic launches new technology platform ventures to revolutionize diagnostic medicine
Mayo Clinic News Network: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians…{post_date: F d, Y}
Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development
HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm…{post_date: F d, Y}